Inimmune gets grant for vaccine technology

By The Science Advisory Board staff writers

July 2, 2020 -- Montana-based Inimmune received a $2 million grant from the U.S. National Institute for Allergy and Infectious Diseases to develop novel adjuvant and delivery systems for vaccines.

The company will develop a stable and safe adjuvant delivery platform against a variety of infectious diseases, including COVID-19. Through the Small Business Innovation Research grant, Inimmune will develop a proprietary synthetic vaccine adjuvant -- components that stimulate and direct the immune system to enhance immunity to a vaccine. The two-year project will be led by Inimmune's Shannon Miller, PhD, and David Burkhart, PhD.

In June, Inimmune announced that they would be collaborating with the University of Montana's Center for Translational Medicine and Rocky Mountain Laboratories for the development of a nasal spray COVID-19 vaccine.

AGC to manufacture adjuvant for Novavax COVID-19 vaccine
AGC Biologics announced it is partnering with Novavax for large-scale good manufacturing practices production of critical components for Novavax's coronavirus...
Codiak partners with Ragon Institue for SARS-CoV-2 vaccine platform
Codiak BioSciences has entered into a strategic collaboration with the Ragon Institute of Massachusetts General Hospital, the Massachusetts Institute...
Codiak presents preclinical results for modular vaccine platform
Codiak BioSciences released new preclinical data on its engEx platform at the American Society of Gene and Cell Therapy annual meeting.

Copyright © 2020 scienceboard.net


Conferences
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter